A Phase 1 Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants
A Phase 1 Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants
A Phase 1 Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants
- 29 January 2025 - 0 mins read

Related Lay Languages

29 January 2025
0 mins read
An Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who...

29 January 2025
0 mins read
An Open Label Efficacy and Safety Study of Palovarotene in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia Ossificans Progressiva (FOP)
08 November 2024
1 mins read
Lipisomal irinotecan compared to standard treatment
09 August 2024
0 mins read
A study to learn about the efficacy and safety of triptorelin 6-month formulation in Chinese children with central precocious puberty
09 August 2024
0 mins read
A study to learn about the effect of strong CYP3A4 boosters or blockers on blood levels of tazemetostat (EPZ-6438) in patients with advanced cancer
09 August 2024
1 mins read
A study in healthy Japanese and non-Asian volunteers to understand what happens to elafibranor in the body when taken by Japanese people compared to non-Asian...
09 August 2024
1 mins read
A study comparing the muscle action potential effects in the foot muscle in healthy male volunteers
09 August 2024
1 mins read
A study to evaluate the effects of the treatment in patients living with spastic hemiparesis in combination with a prescribed personal rehabilitation program
09 August 2024
1 mins read
A study on the effectiveness of the treatment for patients with non-functioning neuroendocrine tumours of the pancreas, intestines or unknown origin.
09 August 2024
1 mins read